| Drug Name |
Temoporfin |
| Drug ID |
BADD_D02149 |
| Description |
Temoporfin is a photosensitizing agent used in the treatment of squamous cell carcinoma of the head and neck [FDA Label]. It was first authorized for market by the European Medicines Agency in October 2001. It is currently available under the brand name Foscan. |
| Indications and Usage |
For use in the treatment of patients with advanced squamous cell carcinoma of the head and neck failing standard therapies and who are unsuitable for radiotherapy, surgery, or systemic chemotherapy [FDA Label]. |
| Marketing Status |
approved; investigational |
| ATC Code |
L01XD05 |
| DrugBank ID |
DB11630
|
| KEGG ID |
D06066
|
| MeSH ID |
C072269
|
| PubChem ID |
60751
|
| TTD Drug ID |
D0P5DG
|
| NDC Product Code |
Not Available |
| UNII |
FU21S769PF
|
| Synonyms |
temoporfin | m-THPC | mTHPC | meso-tetrahydroxyphenyl chlorin | meso-tetrahydroxyphenylchlorin | 5,10,15,20-tetra(m-hydroxyphenyl)chlorin | meso-tetra-(hydroxyphenyl)chlorin | Foscan | Foslip |
